Cancer Care Northwest

Spokane Valley, Washington 99218

4 studies enrolling now · 19 studies all time

What they study most

Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Advanced Multiple Myeloma, Advanced Non-small Cell Lung Cancer, Androgen Resistant Prostatic Cancer, Anemia, Refractory, With Excess of Blasts, Borderline Resectable Pancreatic Cancer, Breast Cancer, Breast Cancer Metastatic, Breast Neoplasm, Early Stage Breast Cancer, End Stage Cancer

Studies at this site

• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence — Recruiting now
• Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies — Recruiting now
• Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. — Recruiting now
• GEMINI-NSCLC: NSCLC Biomarker Study — Recruiting now
• A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer — Running, not enrolling
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma — Running, not enrolling
• Tucatinib+Trastuzumab+Eribulin in HER2+ MBC — Running, not enrolling
• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer — Running, not enrolling
• Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer — Stopped early
• Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer — Completed
• Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer — Stopped early
• Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent — Stopped early
• A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks — Completed
• A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. — Completed
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) — Completed
• A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) — Completed
• Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer — Withdrawn before enrolling
• A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC — Stopped early
• Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies — Completed